Survinin expression in patients with breast cancer during chemotherapy

Autor(es)

Marsicano, S. R. ^[1] ; Kuniyoshi, R. K. ^[1] ; Gehrke, F. S. ^[1] ; Alves, B. C. A. ^[1] ; Azzalis, L. A. ^[2] ; Fonseca, F. L. A. ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] ABC Med Sch, Dept Hematol & Oncol, BR-09060650 Santo Andre - Brazil

^[2] Univ Fed Sao Paulo, Dept Biol Sci, BR-09972270 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: TUMOR BIOLOGY; v. 36, n. 5, p. 3441-3445, MAY 2015.
• Citações Web of Science: 1

Resumo

Breast cancer (BC) is the second most common cancer worldwide and the first among women. If early diagnosed and treated, this disease has a good prognosis. However, it is believed that 90 % of all patients who have had cancer died due to metastatic disease, which highlights the need for a marker which allows the detection of latent cancer cells spread from the primary tumor. The objective of this study was to investigate the expression of survinin in peripheral blood of patients with breast cancer at diagnosis and during chemotherapy aiming correlation with minimal residual disease, clinical and pathological findings. The study included 40 patients with breast cancer and 12 healthy donors as a comparison group. Survinin expression was verified by real-time PCR. For diagnosis, survinin expression cutoff point was 1.05; considering this cutoff point, we obtained a test sensitivity of 85.3 %, specificity of 75.0 %, positive predictive value of 90.6 %, negative predictive value of 64.3 %, and accuracy of 82.6 %. There was statistical significance between groups (patients x control group), presenting to patients a significantly higher value than the control group (p < 0.001). Patients that presented at the diagnosis a survinin gene expression a parts per thousand yen1.05 are 17 times more likely to develop metastatic disease. (AU)

• Processo FAPESP: 11/22746-9 - Estudo de marcadores de células epiteliais através de RT-PCR em tempo real para detecção de células tumorais circulantes (CTCs) na fração mononuclear do sangue periférico de pacientes com câncer de mama durante o tratamento quimioterápico.
• Beneficiário: Sarah Rodrigues Marsicano
• Modalidade de apoio: Bolsas no Brasil - Doutorado